Introduction
============

As a life-threatening disease, cancer is a major contributor to health care burden and increased human mortality.[@b1-ott-11-509] Multiple sequential genetic and epigenetic changes are involved in the process of carcinogenesis. The activation of Gas6/Axl signaling pathway has been found to play an important role during the process of cancer development and progression. The receptor tyrosine kinase Axl belongs to TAM (Tyro3, Axl and Mertk) family and is characterized by an extracellular domain consisting of 2 immunoglobulin-like domains in juxtaposition to 2 fibronectin type III domains, typical for cell adhesion molecules of the immunoglobulin superfamily.[@b2-ott-11-509]--[@b4-ott-11-509] Axl plays a pivotal part in various physiological and pathological processes. When bound to its ligand Gas6, the activated Axl will induce the multiple downstream pathways and lead to resistance of apoptosis, and increased migration and growth.[@b5-ott-11-509]

Upregulation of Gas6/Axl pathway has been found highly related to carcinogenesis.[@b5-ott-11-509] The overexpression of Axl has been underlined in several conditions especially in carcinogenesis. It has been found that Axl is overexpressed in various cancers such as breast cancer, lung cancer and gastrointestinal malignancies. Overexpression of Axl is reported to correlate with poor prognosis.[@b5-ott-11-509] These evidences suggest that Axl could be considered as a potential biomarker for evaluating prognosis in cancer patients.

Although many anti-Axl inhibitors have been developed and launched into Phase I and II clinical trials and have showed some promising results, the comprehensive prognostic value of Gas6/Axl in solid tumors is still not clear.[@b6-ott-11-509] Therefore, we performed this meta-analysis and sought to evaluate the association between Axl expression and prognostic factors including overall survival (OS) and disease-free survival (DFS) in patients with solid tumors. The results of our meta-analysis may provide high-level evidences to verify the prognostic effect of Axl in solid cancers.

Methods
=======

Search strategy and eligible studies
------------------------------------

We performed a comprehensive search of the electronic databases including PubMed, Embase, the Cochrane Library and Web of Science, using the keywords "solid tumor OR cancer OR carcinoma OR neoplasm" AND "Axl OR Gas6 OR ARK OR Tyro7 OR UFO OR AXL receptor tyrosine kinase" AND "prognosis". Both titles and abstracts were carefully screened by 2 independent reviewers to exclude irrelevant studies. Duplicate studies were removed, and additional studies were identified by a manual search of references cited in the original studies. If different studies on same patient population were identified, only the one with the largest patient number was included based on the updated PRISMA criteria.[@b7-ott-11-509] A flow chart of the search process is presented in [Figure 1](#f1-ott-11-509){ref-type="fig"}.

Inclusion and exclusion criteria
--------------------------------

To be eligible for inclusion in this meta-analysis, a study was required to meet the following inclusion criteria: (1) published in English and full text is accessible; (2) provided survival information such as relapse-free survival (RFS) and OS associated with Axl or Gas6 expression; (3) participants must have had a solid tumor; (4) the study should provided hazard ratio (HR) and 95% confidence interval (CI), or data that could be used to estimate the HRs and 95% CIs, or Kaplan--Meier survival curves with sufficient data to extract HRs and 95% CIs; and (5) the study must be a peer-reviewed and published original article. Exclusion criteria: (1) review articles, case reports, letters, comments or book chapters, and studies that had (2) no data on survival or RFS or (3) insufficient data for calculation of HRs.

Data extraction and quality assessment
--------------------------------------

According to the inclusion and exclusion criteria, 2 reviewers (SZ and YXT) searched and assessed the studies independently. Studies were chosen by consensus. The following items were extracted from each study: author, publication year, country, patient number, follow-up period, patient clinicopathological features, Axl/Gas6 detection method, cut-off criteria, statistical method and HR of OS and/or DFS. If HR was not available, we applied GetData Graph Digitizer 2.3 to digitize and extract survival information from the Kaplan--Meier curves. Manual calculation methods were also applied to estimate the HR and 95% CI according to the literature.[@b8-ott-11-509]

Quality assessment of the included studies was performed by 2 independent reviewers (XSX and JXY) according to REMARK (REporting recommendations for tumor MARKer prognostic studies) guideline.[@b9-ott-11-509] As previously published,[@b10-ott-11-509] we used the 20-item scale for quality assessment ([Table 1](#t1-ott-11-509){ref-type="table"}). In brief, this scale includes information on study design, assay method, outcomes and statistical analysis method. Each item is scored as follows: 2 points if it is clearly indicated, 1 point if the description is partial or unclear and 0 point if it is not mentioned in the study. Higher scores represent better quality of the original study.

Statistical analysis
--------------------

Cochrane RevMan 5.3.0 (The Cochrane Collaboration, London, UK) was applied for meta-analysis. Individual HRs and 95% CIs were combined from individual studies to determine the overall effective value of Axl and Gas6. For the overall result, an observed HR \>1 implied that Axl/Gas6 overexpression was a risk factor for OS. The *χ*^2^ test was used to evaluate heterogeneity between studies. A *p*-value \<0.05 indicated that the heterogeneity between individual studies was statistically significant. The total variation among studies was estimated by *I*^2^. An *I*^2^ value \<25% suggested low heterogeneity, and fixed-effects model was used. If heterogeneity was significant, a combined HR was calculated by random-effects model. Publication bias was assessed by Begg's funnel plot and by Egger's linear regression method[@b11-ott-11-509],[@b12-ott-11-509] performed by Stata SE 12.0 (Stata Corp LP, College Station, TX, USA). A *p*-value \>0.05 suggested that there was no significant publication bias. If *p*-value was \<0.05, "trim-and-fill" method was used to test the potential influence of unpublished studies on the summary result.

Results
=======

Search results and characteristics of the eligible studies
----------------------------------------------------------

In total, 544 studies were identified by our search, of which 110 articles were from PubMed and 434 were from other databases ([Figure 1](#f1-ott-11-509){ref-type="fig"}). After removing duplicate studies and screening of titles and abstracts, 43 articles were found to be potentially eligible for our meta-analysis. Eventually, 25 studies fulfilled our inclusion criteria.[@b13-ott-11-509]--[@b37-ott-11-509] Among the included articles, 22 studies[@b14-ott-11-509]--[@b22-ott-11-509],[@b24-ott-11-509]--[@b26-ott-11-509],[@b28-ott-11-509]--[@b37-ott-11-509] had available data to analyze the association between Axl expression and OS, 13 studies[@b14-ott-11-509],[@b18-ott-11-509],[@b21-ott-11-509],[@b22-ott-11-509],[@b27-ott-11-509]--[@b29-ott-11-509],[@b31-ott-11-509],[@b33-ott-11-509]--[@b37-ott-11-509] had available data to analyze the association between Axl expression and DFS and 7 studies[@b13-ott-11-509]--[@b15-ott-11-509],[@b22-ott-11-509]--[@b24-ott-11-509],[@b32-ott-11-509] contained data on Gas6 expression and its relation with OS.

Together, the 25 eligible studies involved 3,344 patients with solid tumor. The sample size of included cohorts ranged from 35 to 509, with a median of 88 patients. In terms of cancer type, 4 studies evaluated breast cancer, followed by hepatocellular carcinoma (n=2), esophageal cancer (n=2), lung cancer (n=2) and other cancer types (glioblastoma multiforme, renal cell carcinoma, pancreatic cancer, oral squamous cell carcinoma (OSCC), ovarian adenocarcinoma, osteosarcoma, nasopharyngeal carcinoma, colorectal cancer, etc). Other information of included studies is summarized in [Table 2](#t2-ott-11-509){ref-type="table"}.

Correlation of Axl expression and OS in all solid tumor patients
----------------------------------------------------------------

As shown in [Figure 2](#f2-ott-11-509){ref-type="fig"}, on pooling data of correlation between OS and Axl expression from 22 studies (3,170 patients), the combined HR was calculated to be 2.03 (95% CI 1.73--2.37, *p*\<0.00001). This indicated that Axl overexpression was associated with a 2.03-fold increase in mortality in all solid tumor patients. No significant heterogeneity across studies was found (*I*^2^=18%, *p*=0.23).

In subgroup analysis of different cancer types, Axl overexpression was correlated with shorter OS in hepatocellular carcinoma, esophageal cancer and lung cancer, with a combined HR of 1.89 (95% CI 1.37--2.60, *p*\<0.0001), 1.99 (95% CI 1.28--3.11, *p*=0.002) and 1.67 (95% CI 1.04--2.67, *p*\<0.03), respectively. For breast cancer, there was no significant correlation between Axl expression and OS, with a combined HR of 1.63 (95% CI 0.69--3.83, *p*=0.27) ([Figure 3A--D](#f3-ott-11-509){ref-type="fig"}).

Impact of Axl expression on DFS in all solid tumor patients
-----------------------------------------------------------

We analyzed the impact of Axl expression on DFS in all solid tumor patients with available data. From 13 studies, the combined HR for impact of Axl overexpression on DFS was 1.85 (1,585 patients, 95% CI 1.44--2.38, *p*\<0.00001), which indicated that the overexpression of Axl increases the risk of disease recurrence by 1.85-fold ([Figure 4](#f4-ott-11-509){ref-type="fig"}). No significant heterogeneity was detected among studies (*I*^2^=37%, *p*=0.09).

Impact of Gas6 expression on OS in all solid tumor patients
-----------------------------------------------------------

The correlation of OS and Gas6 expression was analyzed in 7 studies with a total of 807 patients. As illustrated in [Figure 5](#f5-ott-11-509){ref-type="fig"}, the combined HR was 1.22 (95% CI 0.77--1.93, *p*=0.39), which suggested that the accumulated data did not show significant correlation between Gas6 expression and OS. In addition, significant heterogeneity across studies was found (*I*^2^=58%, *p*=0.03).

Correlation between Axl expression and clinicopathological characteristics
--------------------------------------------------------------------------

We found that Axl overexpression was correlated with poor prognosis in all solid tumors. To further analyze the correlation between Axl and clinicopathological characteristics, we performed a meta-analysis with the available data. In all the included studies, Axl expression was significantly associated with poor (poor vs well or moderate) differentiation grade (1,227 patients; pooled odds ratio \[OR\]: 1.95, 95% CI 1.29--2.97, *p*=0.002), advanced (stage III/IV) TNM stage (804 patients; pooled OR: 2.81, 95% CI 1.65--4.80, *p*=0.002), lymph node metastasis (613 patients; pooled OR: 2.99, 95% CI 1.54--5.79, *p*=0.001) and distant metastasis (374 patients; pooled OR: 4.14, 95% CI 2.20--7.79, *p*\<0.0001) ([Figure 6A--D](#f6-ott-11-509){ref-type="fig"}).

Assessment of publication bias
------------------------------

We evaluated the publication bias of the correlation between Axl expression and OS and DFS. As shown in [Figure 7A and B](#f7-ott-11-509){ref-type="fig"}, the funnel plots were symmetrical. In addition, Egger's test showed no significant publication bias in meta-analysis of OS and DFS (*p*=0.55 and *p*=0.19, respectively). In addition, there was no significant publication bias in meta-analysis of Gas6 expression and OS ([Figure 8](#f8-ott-11-509){ref-type="fig"}), with a symmetrical funnel plot. Begg's regression (*p*=1) and Egger's linear regression (*p*=0.556) also confirmed the result.

Discussion
==========

It has been widely studied and proved that the activation of Gas6/Axl pathway is implicated in the development and progression of cancer. The activation of Axl is dependent on its overexpression as it has been found overexpressed in various malignancies[@b5-ott-11-509] and related to poor prognosis. To the best of our knowledge, this meta-analysis is the first and most comprehensive study to systematically explore the impact of Axl and Gas6 expression on prognosis in various solid malignancies.

In the present study, we included 25 studies with 3,344 patients and analyzed whether Axl is a significant prognostic risk factor in solid tumors. In general, Axl was overexpressed in cancerous tissue compared to normal control tissue (average: 54.7% vs 12.7%) ([Table S1](https://www.dovepress.com/get_supplementary_file.php?f=150952.pdf)). First, we analyzed the overall impact of Axl expression on OS from 22 studies. Our results demonstrated that Axl overexpression significantly correlated with a 2.03-fold (95% CI 1.73--2.37) increase in mortality in all solid tumor patients. In terms of DFS, the meta-analysis of 13 studies indicated that overexpression of Axl was significantly correlated with a shorter DFS time, with a pooled HR of 1.85 (95% CI 1.44--2.38). No significant heterogeneity and publication bias were detected among studies, which suggested that our results of Axl overexpression indicating poor OS and DFS are convincing. As Axl expression was relatively high in cancerous tissue (54.7%) compared to normal counterpart (12.7%), Axl can be used as a sensitive and potent indicator for predicting outcome of solid malignancies.

Furthermore, we stratified the results by different cancer types. Our subgroup analysis showed that Axl overexpression was correlated with decreased OS in hepatocellular carcinoma (OR: 1.89, 95% CI 1.37--2.60), esophageal cancer (OR: 1.99, 95% CI 1.28--3.11) and lung cancer (OR: 1.67, 95% CI 1.04--2.67). The subgroup results are in concordance with previous in vitro data. In hepatocellular cancer cell lines, Gas6/Axl can enhance cell invasiveness through transcriptional activation of *Slug* which induces epithelial--mesenchymal transition (EMT).[@b38-ott-11-509] Studies also found that Axl overexpression correlated with enhanced cell motility and invasiveness in lung cancer.[@b39-ott-11-509] In addition, activation of Axl could cause resistance of EGFR-targeted therapy in lung cancer.[@b40-ott-11-509] In esophageal cancer, it has been shown that genetic silencing of Axl can inhibit proliferation, migration and invasion.[@b41-ott-11-509] Although many studies provided substantial evidences of Axl's biological significance in breast cancer development,[@b42-ott-11-509]--[@b44-ott-11-509] our meta-analysis failed to show significant correlation between Axl expression and OS in breast cancer patients. More translational studies are needed to further explore the role of Axl signaling pathway in breast cancer.

Clinical parameters such as differentiation grade, lymph node involvement, distant metastasis and TNM stages are critical factors to predict outcomes in solid tumors. Studies have demonstrated that Gas6/Axl pathway activation could initiate EMT process and enhance cancer cell invasiveness.[@b45-ott-11-509] In our meta-analysis, we evaluated the relationship between Axl expression and various clinicopathological characteristics. Our results indicated that poor differentiation (OR: 1.95, 95% CI 1.29--2.97), advanced TNM stage (OR: 2.81, 95% CI 1.65--4.80), positive lymph node metastasis (OR: 2.99, 95% CI 1.54--5.79) and positive distant metastasis (OR: 4.14, 95% CI 2.20--7.79) are correlated with Axl overexpression. These findings suggest that Axl could serve as a valuable predicting factor in solid tumors.

As the major ligand of Axl, Gas6 may activate Axl signaling pathway and initiate its downstream events. Researchers have found that Gas6 is overexpressed in certain cancers compared to normal adjacent tissues[@b46-ott-11-509] and can enhance cancer cell viability and motility in vitro.[@b47-ott-11-509] Jiang et al also proved that in OSCC patients, serum Gas6 level is elevated and it can be an independent factor to predict prognosis (HR from multivariate analysis: 2.07, *p*\<0.05).[@b48-ott-11-509] Due to limited number of included studies, our meta-analysis of relationship between Gas6 expression and OS showed no statistical significance. However, we noted that there is significant heterogeneity between studies (*I*^2^=58%). We therefore conducted the sensitivity examination by deleting single study from the meta-analysis and found that if the study by Akitake-Kawano et al[@b23-ott-11-509] was removed, the pooled HR for the effect of Gas6 overexpression on OS would be 1.44 (95% CI 1.02--2.04, *p*=0.04) and the heterogeneity was eliminated (*I*^2^=27%) ([Figure S1](https://www.dovepress.com/get_supplementary_file.php?f=150952.pdf)). This discrepancy might be due to the following possibility: (1) insufficient studies were included; (2) heterogeneity between different types of solid tumors was poor; and (3) Gas6 has a complex pathophysiological role. Unlike Axl, Gas6 is a secreted protein that is usually released into circulation. In terms of cancer development, it is still not clear whether tumor tissues secrete Gas6 to facilitate cancer cell proliferation or other stromal cells secrete Gas6 to support tumor growth. To answer this question, more studies are needed to elucidate the underlining mechanism.

According to our comprehensive quality assessment system, all included studies had moderate- to high-quality scores ([Table S2](https://www.dovepress.com/get_supplementary_file.php?f=150952.pdf)). Apart from the animating results, there are several limitations of this meta-analysis. First, although it included various types of cancers, there is limited number of studies for each specific cancer type. It is inconclusive whether Axl expression correlates with OS in a specific type of cancer. Second, impact of Gas6 expression on OS is still inconclusive. Gas6 and Axl expression might be detected together in future study to explore whether it is more accurate in predicting outcome. Third, different staining protocols, reagents and cut-off evaluation were applied in individual studies. This heterogeneity was difficult to eliminate which may generate bias in the overall result. Finally, although random-effect model was applied, heterogeneity between studies still existed and this may affect the overall result. Thus, more high-quality studies are needed to draw more reliable conclusions.

In spite of the limitations mentioned above, this comprehensive meta-analysis has many valuable implications. First, the present study evaluated for the first time the prognostic value of Axl expression in all solid tumor patients. We demonstrated and validated that Axl is a prognostic factor for unfavorable outcome in solid tumor. Second, we also proved that Axl overexpression is correlated with clinical parameters such as advanced stage, poor differentiation grade, lymph node metastasis and distant metastasis. In conclusion, according to our meta-analysis, Axl is a promising biomarker for predicting prognosis in solid tumor. Our results may provide evidence for further research on biological role of Gas6/Axl axis in a specific type of cancer.
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![Flow chart of the selection process.\
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![Forest plot of the hazard ratio for overall survival associated with Axl expression in all solid tumor patients.\
**Abbreviations:** CI, confidence interval; IV, inverse variance; SE, standard error.](ott-11-509Fig2){#f2-ott-11-509}

![Forest plots of the hazard ratio for overall survival associated with Axl expression in breast cancer (**A**), liver cancer (**B**), esophageal cancer (**C**) and lung cancer (**D**).\
**Abbreviations:** CI, confidence interval; IV, inverse variance; SE, standard error.](ott-11-509Fig3){#f3-ott-11-509}

![Forest plot of the hazard ratio for disease-free survival associated with Axl expression in all solid tumor patients.\
**Abbreviations:** CI, confidence interval; IV, inverse variance; SE, standard error.](ott-11-509Fig4){#f4-ott-11-509}

![Forest plot of the hazard ratio for overall survival associated with Gas6 expression in all solid tumor patients.\
**Abbreviations:** CI, confidence interval; IV, inverse variance; SE, standard error.](ott-11-509Fig5){#f5-ott-11-509}

![Relationship between Axl expression and poor differentiation grade (**A**), late (III/IV stage) TNM stage (**B**), lymph node metastasis (**C**) and distant metastasis (**D**) in all solid tumor patients.\
**Abbreviations:** CI, confidence interval; LN, lymph node; M--H, Mantel--Haenszel.](ott-11-509Fig6){#f6-ott-11-509}

![Funnel plots of HR of Axl expression for OS (**A**) and DFS (**B**) in all solid tumor patients.\
**Abbreviations:** DFS, disease-free survival; HR, hazard ratio; Ln, natural logarithm; OS, overall survival; SE, standard error.](ott-11-509Fig7){#f7-ott-11-509}

![Funnel plot of HR of Gas6 expression for OS in all solid tumor patients.\
**Abbreviations:** HR, hazard ratio; OS, overall survival; SE, standard error.](ott-11-509Fig8){#f8-ott-11-509}

###### 

Items for quality assessment

  Item                    Item description
  ----------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Introduction            
   Item 1                 Give rationale for study hypothesis and objectives
  Materials and methods   
   Patients               
    Item 2                Describe patient characteristics: list all candidate variables (eg, age, menopause status, disease type, etc)
    Item 3                Describe treatment received by the patients
   Specimen               
    Item 4                Describe type of the specimen and control samples
   Assay methods          
    Item 5                Describe in details the methods used to detect Axl/Gas6 (eg, quantitative PCR or immunohistochemical staining, etc)
    Item 6                Manufacturer and catalog number for reagents
    Item 7                Evaluation methods: cut-off point determination
    Item 8                Negative and positive control and blind methods applied
   Study design           
    Item 9                Give rationale for sample size
    Item 10               Case selection criteria: state inclusion and/or exclusion criteria; whether prospective or retrospective; whether stratification or matching was employed; the period from which cases were taken
    Item 11               Follow-up description: follow-up period or median follow-up time
    Item 12               Outcome description: define all clinical end points examined
   Statistical analysis   
    Item 13               Specify all statistical methods and information (methods to analyze correlation of Axl/Gas6 expression and clinical parameters, methods to analyze overall survival and/or disease-free survival, *p*-value, statistical software applied)
  Results                 
   Data and analysis      
    Item 14               Describe Axl/Gas6 expression in all solid cancer patients and its correlation to standard prognostic variables
    Item 15               Present univariate analyses showing the relation between Axl/Gas6 and outcome, with estimated effect (eg, hazard ratio)
    Item 16               For multivariate analyses, report estimated effects (eg, hazard ratio) with confidence interval for Axl/Gas6, adjusted for other risk factors
    Item 17               Missing data: describe the missing number value for Axl/Gas6 and how to deal with it
  Discussion              
   Item 18                Interpret the results in the context of hypotheses and other relevant studies
   Item 19                Discussion of potential confounding factor of the study
   Item 20                Discussion of limitation of the study, clinical value of Axl/Gas6 and implication for future investigation

###### 

Characteristics of studies included in meta-analysis

  Reference                               Year   Country           Cancer type                            Patients (n)   Stage     Median follow-up (months)   Method   Detection      HR estimation                Statistic      HR (95% CI) of OS      Quality score (%)
  --------------------------------------- ------ ----------------- -------------------------------------- -------------- --------- --------------------------- -------- -------------- ---------------------------- -------------- ---------------------- -------------------
  Mc Cormack et al[@b13-ott-11-509]       2008   Ireland           Breast cancer                          49             I--IV     42                          qPCR     Gas6           Calculated from K--M curve   Multivariate   0.36 (0.09--1.44)      70%
  Hutterer et al[@b14-ott-11-509]         2008   Singapore         Glioblastoma multiforme                76             N/A       102                         IHC      Axl and Gas6   Calculated from K--M curve   Multivariate   2.39 (0.75--7.57)      83%
  Gustafsson et al[@b15-ott-11-509]       2009   Sweden            Renal cell carcinoma                   308            I--IV     143.4                       qPCR     Axl and Gas6   Given by author              Multivariate   2.178 (1.278--3.712)   68%
  Gjerdrum et al[@b16-ott-11-509]         2010   Norway            Esophageal cancer                      154            I--IV     72                          IHC      Axl            Calculated                   Multivariate   3.27 (1.21--8.84)      73%
  Hector et al[@b17-ott-11-509]           2010   USA               CRC                                    92             I--IV     NR                          TMA      Axl            Given by author              Multivariate   1.91 (1.04--3.49)      80%
  Song et al[@b18-ott-11-509]             2011   USA               Pancreatic cancer                      54             II        NR                          IHC      Axl            Given by author              Multivariate   2.4 (1.08--5.29)       78%
  Lee et al[@b19-ott-11-509]              2012   Taiwan            Oral squamous cell carcinoma           112            I--IV     NR                          IHC      Axl            Given by author              Multivariate   2.000 (1.042--3.839)   70%
  Chen et al[@b20-ott-11-509]             2013   China             Ovarian carcinoma                      80             I--IV     NR                          IHC      Axl            Given by author              Multivariate   2.323 (1.21--4.462)    75%
  Han et al[@b21-ott-11-509]              2013   China             Osteosarcoma                           62             N/A       75                          IHC      Axl            Calculated                   Multivariate   1.385 (0.539--3.641)   75%
  Ishikawa et al[@b22-ott-11-509]         2013   Japan             Lung cancer                            88             N/A       NR                          IHC      Axl and Gas6   Given by author              Multivariate   3.23 (1.85--9.09)      80%
  Akitake-Kawano et al[@b23-ott-11-509]   2013   Japan             Colorectal cancer                      62             III--IV   NR                          IHC      Gas6           Calculated from K--M curve   Univariate     0.30 (0.10--0.89)      65%
  Pinato et al[@b24-ott-11-509]           2013   Italy             Malignant pleural mesothelioma         63             I--IV     NR                          IHC      Axl and Gas6   Given by author              Multivariate   3.34 (1.25--5)         78%
  Dunne et al[@b25-ott-11-509]            2014   Singapore         Colorectal cancer                      509            II        NR                          IHC      Axl            Given by author              Multivariate   2.217 (1.148--4.281)   68%
  Fleuren et al[@b26-ott-11-509]          2014   the Netherlands   Ewing's sarcoma                        35             N/A       66                          IHC      Axl            Given by author              Multivariate   18.00 (1.2--255.74)    75%
  Brand et al[@b27-ott-11-509]            2015   USA               Head and neck cancer                   63             N/A       NR                          TMA      Axl            Given by author              Multivariate   2.3 (1.1--5.1)         73%
  Hsieh et al[@b28-ott-11-509]            2016   Taiwan            Esophageal cancer                      116            I--III    NR                          IHC      Axl            Given by author              Multivariate   2.09 (1.09--4.04)      78%
  Jiang et al[@b29-ott-11-509]            2016   China             Nasopharyngeal carcinoma               86             I--IV     NR                          IHC      Axl            Given by author              Multivariate   1.85 (1.02--3.35)      73%
  Qu et al[@b30-ott-11-509]               2015   China             Lung cancer                            134            I--IV     NR                          TMA      Axl            Given by author              Multivariate   1.406 (0.830--2.383)   73%
  Reichl et al[@b31-ott-11-509]           2015   Austria           Hepatic cancer                         133            I--IV     NR                          TMA      Axl            Given by author              Multivariate   2.053 (1.026--4.108)   53%
  Hattori et al[@b32-ott-11-509]          2016   Japan             Urothelial carcinoma                   161            N/A       66.1                        IHC      Axl and Gas6   Given by author              Multivariate   3.32 (1.25--8.81)      85%
  Liu et al[@b33-ott-11-509]              2016   China             Hepatic cancer                         246            I--III    N/A                         TMA      Axl            Given by author              Multivariate   1.847 (1.291--2.642)   80%
  Roland et al[@b34-ott-11-509]           2016   USA               Undifferentiated pleomorphic sarcoma   208            N/A       46.8                        IHC      Axl            Given by author              Univariate     1.52 (0.94--2.5)       70%
  Tanaka et al[@b35-ott-11-509]           2016   Japan             Breast cancer                          343            I--III    84                          IHC      Axl            Given by author              Univariate     1.34 (0.64--2.89)      80%
  Wang et al[@b36-ott-11-509]             2016   China             Breast cancer                          50             I--III    43                          IHC      Axl            Calculated                   Univariate     3.61 (1.11--11.76)     65%
  Jin et al[@b37-ott-11-509]              2017   China             Breast cancer                          60             I--III    60                          IHC      Axl            Calculated                   Univariate     0.48 (0.17--1.37)      78%

**Abbreviations:** CI, confidence interval; CRC, colorectal carcinoma; HR, hazard ratio; IHC, immunohistochemistry; K--M, Kaplan--Meier; N/A, not available; NR, not reported; OS, overall survival; qPCR, quantitative PCR; TMA, tissue microarray.
